Harmony Biosciences Quarterly Cash Flow Statement
NASDAQ: HRMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Harmony Biosciences free cash flow
In the quarter ended Jun 30, 2026, Harmony Biosciences generated $92.4 million of operating cash flow. That left free cash flow of $92.4 million, a free-cash-flow margin of 35.4% of revenue. Free cash flow was up 16.5% from the prior year's $79.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Harmony Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 75.43M | 32.49M | 22.49M | 50.87M | 39.78M | 45.56M | 49.48M | 46.09M | 11.59M | 38.33M | 26.61M | 38.46M |
| Net Income growth (YoY) | +89.64% | -28.69% | -54.55% | +10.35% | +243.16% | +18.85% | +85.95% | +19.84% | -66.21% | +30.01% | -45.15% | -56.27% |
| Depreciation & Amortization | 7.00K | 7.00K | — | 7.00K | 6.00K | 7.00K | 6.00K | 7.00K | 91.00K | 163.00K | 164.00K | 144.00K |
| Stock-Based Compensation | 9.34M | 10.62M | 9.97M | 10.97M | 11.46M | 12.50M | 10.07M | 11.05M | 11.09M | 10.39M | 8.86M | 7.99M |
| Change in Working Capital | 4.25M | -49.63M | 74.04M | 30.14M | 13.50M | -25.86M | 15.82M | 11.70M | -14.51M | -20.33M | 31.64M | 6.73M |
| Operating Cash Flow | 92.43M | 27.76M | 126.15M | 108.73M | 79.33M | 33.99M | 75.56M | 70.50M | 42.62M | 31.14M | 76.67M | 63.10M |
| Capital Expenditures | — | — | -107.00K | -71.00K | -4.00K | -128.00K | -513.00K | -3.00K | -632.00K | -5.00K | -107.00K | 0 |
| Investing Cash Flow | -131.50M | -183.65M | -17.63M | -4.79M | -19.59M | 2.36M | -7.19M | 745.00K | -54.86M | -6.19M | -36.06M | -813.00K |
| Share Repurchases | — | — | — | — | — | — | — | — | — | — | -50.00M | — |
| Debt Issued | — | — | — | — | — | — | — | — | — | — | 0 | — |
| Debt Repaid | -5.00M | -5.00M | -5.00M | -3.75M | -3.75M | -3.75M | -3.75M | -3.75M | -3.75M | -3.75M | -3.75M | 0 |
| Financing Cash Flow | -558.00K | -7.22M | -3.02M | -3.00M | -2.69M | -352.00K | -2.74M | -1.18M | -3.45M | -3.63M | -53.52M | -55.10M |
| Net Change in Cash | -39.63M | -163.10M | 105.50M | 100.95M | 57.05M | 36.00M | 65.63M | 70.07M | -15.69M | 21.32M | -12.92M | 7.19M |
| Free Cash Flow | 92.43M | 27.76M | 126.04M | 108.66M | 79.32M | 33.86M | 75.05M | 70.50M | 41.98M | 31.14M | 76.56M | 63.10M |
This table shows 12 quarterly periods of Harmony Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow HRMY's reporting calendar. What is a cash flow statement?